论文部分内容阅读
本研究检测未治疗、未缓解/复发及缓解期间急性髓系白血病(AML)和其他良性血液病患者骨髓细胞中eIF4E基因表达水平并分析其与疾病进展的关系。采用SYBR Green I荧光定量PCR和相对定量分析法检测30例AML患者(M2型6例,M3型5例,M4型8例,M5型10例,M6型1例),11例AML化疗后完全缓解患者和20例非肿瘤性血液病患者骨髓单个核细胞的eIF4E表达情况,以β2微球蛋白基因(β2M)作为内参,采用公式2-△Ct×100%计算eIF4E基因表达水平。结果表明:AML未治疗及未缓解/复发组患者骨髓细胞eIF4E表达水平(7.098±5.544)%明显高于非肿瘤患者(0.248±0.163)%(P<0.01)和化疗后完全缓解患者(0.964±0.312)%(P<0.01),各AML亚型之间不存在统计学差异,尽管M4、M5亚型的表达水平相对较高。非白血病患者与缓解患者比较,eIF4E表达水平不存在显著性差异。结论:eIF4E基因在急性髓系白血病细胞中出现高表达,并随着疾病的缓解而明显降低,因此eIF4E有可能作为监测白血病进展的一项参数。
This study examined eIF4E gene expression in bone marrow cells of patients with acute myeloid leukemia (AML) and other benign blood diseases in untreated, unremitting / relapsed and refractory patients and analyzed its association with disease progression. 30 AML patients (6 M2, 5 M3, 8 M4, 10 M5 and 1 M6) were detected by SYBR Green I quantitative real-time PCR and relative quantitative analysis. EIF4E expression in bone marrow mononuclear cells from patients and 20 patients with non-neoplastic hematologic diseases was alleviated. The β2 microglobulin gene (β2M) was used as an internal control to calculate eIF4E gene expression using the formula 2-Δ Ct × 100%. The results showed that the expression of eIF4E in bone marrow cells (7.098 ± 5.544)% in AML untreated and unremitting / relapsed patients was significantly higher than that in non-neoplastic patients (0.248 ± 0.163)% (P <0.01) and in patients with complete remission after chemotherapy (0.964 ± 0.312)% (P <0.01). There was no statistical difference between the AML subtypes, though the expression levels of M4 and M5 subtypes were relatively high. There was no significant difference in eIF4E expression between non-leukemia and remission patients. CONCLUSION: The eIF4E gene is highly expressed in acute myeloid leukemia cells and is significantly reduced with the alleviation of the disease. Therefore, eIF4E may be used as a parameter to monitor the progress of leukemia.